SynthesisAlzheimer's research & therapy2026
Association between amyloid-β deposition and cognitive function in cognitively normal adults: a multilevel meta-analysis.
Synthesis in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe association between cerebral amyloid-β (Aβ) burden and cognitive performance in cognitively normal (CN) older adults remains uncertain. This meta-analysis aimed to provide an updated and modality-sensitive synthesis of the relationship between Aβ burden and cognitive performance in CN ageing.
methodsWe searched major electronic databases for observational studies investigating the relationship between Aβ biomarkers (positron emission tomography [PET], cerebrospinal fluid [CSF], or plasma) and cognitive outcomes in CN adults. Effect sizes were transformed to Fisher’s z. To account for within-study dependencies, we applied a multilevel random-effects meta-analytic model, followed by subgroup analyses by biomarker modality, study design, and cognitive domain.
resultsSixty-two studies involving 27,320 CN participants (197 effect sizes) met the inclusion criteria. Overall, higher Aβ burden was modestly but significantly associated with poorer cognition (Fisher’s z = − 0.092, p < 0.001), with substantial heterogeneity. Modality-specific analyses showed significant negative associations for PET (Fisher’s z = − 0.098, p < 0.001) and plasma (Fisher’s z = − 0.103, p = 0.012), but not for CSF. By study design, significant associations were observed in both longitudinal studies (Fisher’s z = − 0.109, p = 0.002) and cross-sectional studies (Fisher’s z = − 0.070, p = 0.002). By cognitive domain, the association appeared to be strongest for episodic memory (Fisher’s z = − 0.156, p < 0.001), with significant associations also noted for global cognition, language, executive function, and attention (Fisher’s z = − 0.130 to − 0.057, p ≤ 0.038). DISCUSSION: In CN ageing, higher Aβ burden was associated with slightly poorer cognition. Associations were more consistently detected for PET-based measures and were most pronounced for episodic memory. These findings highlight the importance of biomarker modality and domain-targeted outcomes in preclinical AD research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.